Jump to content

Virotherapy: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
Line 24: Line 24:
{{Main article|Oncolytic virus}}
{{Main article|Oncolytic virus}}


The oncolytic virus [[Rigvir]] developed at the Institute of Microbiology in [[Latvia]] was registered in 2004 in Latvia (national registration).<ref>{{cite web|author=Latvian State Agency of Medicines Registry |url=http://www.zva.gov.lv/zalu-registrs/?iss=1&lang=en&q=Rigvir&ON=&SN=&NAC=on&RN=&ESC=on&AK=&SAT=on&RA=&DEC=on&LB=&PIM=on |title=Medicinal product register of the Republic of Latvia | accessdate=21 January 2015}}</ref> This wild-type nonpathogenic enteric cytopathic human orphan type 7 (ECHO-7) virus was the first to be granted national regulatory approval<ref>{{cite journal|last1=Duffy|first1=M.R.|last2=Fisher|first2=K.D.|last3=Seymour|first3=L.W.|title=Making Oncolytic Virotherapy a Clinical Reality: The European Contribution|journal=Human Gene Therapy|date=November 2017|volume=28|issue=11|pages=1033-1046|doi=10.1089/hum.2017.112|pmid=28793793|publisher=M.A. Liebert Country of Publication: United States NLM|issn=15577422|id=9008950}}</ref> and since 2004 Rigvir is approved and from 2008 Rigvir is available in pharmacies of Latvia. Also in 2015 Rigvir was included into the Latvian National guidelines for treatment of skin cancer and melanoma.<ref>{{cite web|title=Cancer Virotherapy Journal |url= https://www.cancervirotherapy.eu/cancer-virotherapy-pdf-version.php | accessdate=23 November 2015}}</ref> Since 2015 Rigvir is approved in Georgia, but in 2016 it was approved in Armenia. Since then Rigvir registration in Latvia has become under questioning, because of complete lack of appropriately documented efficiacy, and unethical (and occasionally unlawful) practices of its sellers.
The oncolytic virus [[Rigvir]] developed at the Institute of Microbiology in [[Latvia]] was registered in 2004 in Latvia (national registration).<ref>{{cite web|author=Latvian State Agency of Medicines Registry |url=http://www.zva.gov.lv/zalu-registrs/?iss=1&lang=en&q=Rigvir&ON=&SN=&NAC=on&RN=&ESC=on&AK=&SAT=on&RA=&DEC=on&LB=&PIM=on |title=Medicinal product register of the Republic of Latvia | accessdate=21 January 2015}}</ref> This wild-type nonpathogenic enteric cytopathic human orphan type 7 (ECHO-7) virus was the first to be granted national regulatory approval<ref>{{cite journal|last1=Duffy|first1=M.R.|last2=Fisher|first2=K.D.|last3=Seymour|first3=L.W.|title=Making Oncolytic Virotherapy a Clinical Reality: The European Contribution|journal=Human Gene Therapy|date=November 2017|volume=28|issue=11|pages=1033-1046|doi=10.1089/hum.2017.112|pmid=28793793|publisher=M.A. Liebert Country of Publication: United States NLM|issn=15577422|id=9008950}}</ref> and since 2004 Rigvir is approved and from 2008 Rigvir is available in pharmacies of Latvia. Also in 2015 Rigvir was included into the Latvian National guidelines for treatment of skin cancer and melanoma.<ref>{{cite web|title=Cancer Virotherapy Journal |url= https://www.cancervirotherapy.eu/cancer-virotherapy-pdf-version.php | accessdate=23 November 2015}}</ref> Since 2015 Rigvir is approved in Georgia, but in 2016 it was approved in Armenia. Regarding the historical background, ECHO -7 has been studied by scientific teams in the Soviet Union (Soviet Latvia) led by Aina Muceniece with initial reports from her group in the 1960s and 1970s. The empirical roots of the soviet science and the mentioned regulatory approvals, have apparent limitations and do not appear to be supported by clinical data of the rigor that is typically warranted in the US, European Union and Japan, considered to be the most rigorous in the regulatory review of novel cancer therapeutics. However, despite these limitations on the available data, the story of Rigvir remains worth exploring with the implementation of critical reasoning, given that it is a wild-type virus, among other viruses, and hence could rapidly undergo translation if safety and efficacy can be confirmed by other investigators. For example, a potential benefit for Rigvir in comparison to T-VEC includes potential for higher specificity of cancer cells as the latter is taken up by normal cells. Again, there is currently insufficient information to compare both oncolytic viruses due to the lack of prospective and comparative trials, but the available retrospective clinical case studies demonstrate the effort being applied towards sufficient and formally acceptable scientific approval.<ref>{{cite journal|last1=Babiker|first1=H.M.|last2=Riaz|first2=I.B.|last3=Husnain|first3=M.|last4=Borad|first4=M.J.|title=Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.|journal=Oncolytic Virotherapy.|date=February 2017|volume=6|pages=11-18|doi=10.2147/OV.S100072|pmid=28224120|publisher=Dovepress, New Zealand NLM|issn=22531572|id=101629828}}</ref> Since then Rigvir registration in Latvia has become under intense scrutiny and questioning. There are intensive local accusations of complete lack of appropriately documented efficacy, and unethical (and occasionally unlawful) practices of its sellers. However, this negative background is significantly reinforced by political and business culture distinctive for post-soviet regions, like Latvia.


In 2004, researchers from [[University of Texas]] genetically programmed a type of [[common cold]] virus Adenovirus Delta-24-RGD to attack [[glioblastoma multiforme]]. Delta-24-RGD is a replication-competent virus that is genetically engineered to induce selective cancer cell lysis. In cancer cells, Delta-24-RGD induces massive autophagy, which is required for efficient cell lysis and adenoviral spread.<ref>{{cite journal|last1=Klein|first1=S.R.|last2=Piya|first2=S.|last3=Lu|first3=Z.|last4=Xia|first4=Y.|last5=Alonso|first5=M.M.|last6=White|first6=E.J.|last7=Wei|first7=J.|last8=Gomez-Manzano|first8=C.|last9=Jiang|first9=H.|last10=Fueyo|first10=J.|title=C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy.|journal=Oncogene|date=January 2015|volume=34|issue=41|pages=5295-5301|doi=10.1038/onc.2014.452|publisher=Nature Publishing Group|issn=09509232}}</ref> Later other researchers<ref>{{cite journal|vauthors=Witlox AM, Van Beusechem VW, Molenaar B, Bras H, Schaap GR, Alemany R, Curiel DT, Pinedo HM, Wuisman PI, Gerritsen WR|title= Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo|journal=Clin. Cancer Res.|year=2004 |volume=10|issue=Pt 1|pages=61–67|pmid=14734452|doi=10.1158/1078-0432.ccr-0609-03}}</ref> have tried tests on mice where 9 out of 10 mice have shown degeneration of tumours and prolonged survival. A drug grade virus was approved for clinical trials on humans in 2009.<ref>[http://clinicaltrials.gov/ct2/show/study/NCT00805376?show_desc=Y#desc Clinical Trial for Delta-24-RGD for Recurrent Malignant Gliomas]</ref>
In 2004, researchers from [[University of Texas]] genetically programmed a type of [[common cold]] virus Adenovirus Delta-24-RGD to attack [[glioblastoma multiforme]]. Delta-24-RGD is a replication-competent virus that is genetically engineered to induce selective cancer cell lysis. In cancer cells, Delta-24-RGD induces massive autophagy, which is required for efficient cell lysis and adenoviral spread.<ref>{{cite journal|last1=Klein|first1=S.R.|last2=Piya|first2=S.|last3=Lu|first3=Z.|last4=Xia|first4=Y.|last5=Alonso|first5=M.M.|last6=White|first6=E.J.|last7=Wei|first7=J.|last8=Gomez-Manzano|first8=C.|last9=Jiang|first9=H.|last10=Fueyo|first10=J.|title=C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy.|journal=Oncogene|date=January 2015|volume=34|issue=41|pages=5295-5301|doi=10.1038/onc.2014.452|publisher=Nature Publishing Group|issn=09509232}}</ref> Later other researchers<ref>{{cite journal|vauthors=Witlox AM, Van Beusechem VW, Molenaar B, Bras H, Schaap GR, Alemany R, Curiel DT, Pinedo HM, Wuisman PI, Gerritsen WR|title= Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo|journal=Clin. Cancer Res.|year=2004 |volume=10|issue=Pt 1|pages=61–67|pmid=14734452|doi=10.1158/1078-0432.ccr-0609-03}}</ref> have tried tests on mice where 9 out of 10 mice have shown degeneration of tumours and prolonged survival. A drug grade virus was approved for clinical trials on humans in 2009.<ref>[http://clinicaltrials.gov/ct2/show/study/NCT00805376?show_desc=Y#desc Clinical Trial for Delta-24-RGD for Recurrent Malignant Gliomas]</ref>

Revision as of 09:05, 16 April 2018

Virotherapy is a treatment using biotechnology to convert viruses into therapeutic agents by reprogramming viruses to treat diseases. There are three main branches of virotherapy: anti-cancer oncolytic viruses, viral vectors for gene therapy and viral immunotherapy. In a slightly different context, virotherapy can also refer more broadly to the use of viruses to treat certain medical conditions by killing pathogens.

Oncolytic virotherapy

Oncolytic virotherapy is not a new idea – as early as the mid 1950s doctors were noticing that cancer patients who suffered a non-related viral infection, or who had been vaccinated recently, showed signs of improvement;[1] this has been largely attributed to the production of interferon and tumour necrosis factors in response to viral infection, but oncolytic viruses are being designed that selectively target and lyse only cancerous cells.

In the 1940s and 1950s, studies were conducted in animal models to evaluate the use of viruses in the treatment of tumours.[2] In the 1940s–1950s some of the earliest human clinical trials with oncolytic viruses were started.[3][4] However, for several years research in this field was delayed due to the inadequate technology available. Research has now started to proceed more quickly in finding ways to use viruses therapeutically.

As well as the direct anti-cancer effect, oncolytic viruses are also capable of inducing an anti-tumour immune response.

Viral gene therapy

Viral gene therapy most frequently uses non-replicating viruses to deliver therapeutic genes to cells with genetic malfunctions. Early efforts while technically successful, faced considerable delays due to safety issues as the uncontrolled delivery of a gene into a host genome has the potential to disrupt tumour suppressing genes and induce cancer, and did so in two cases. Immune responses to viral therapies also pose a barrier to successful treatment, for this reason eye therapy for genetic blindness is attractive as the eye is an immune privileged site, preventing an immune response.

An alternative form of viral gene therapy is to deliver a gene which may be helpful in preventing disease that would not normally be expressed in the natural disease condition. For example, the growth of new blood vessels in cancer, known as angiogenesis, enables tumours to grow larger. However, a virus introducing anti-angiogenic factors to the tumour may be able to slow or halt growth.

Viral immunotherapy

Viral immunotherapy uses viruses to introduce specific antigens to the patient's immune system. Unlike traditional vaccines, in which attenuated or killed virus/bacteria is used to generate an immune response, viral immunotherapy uses genetically engineered viruses to present a specific antigen to the immune system. That antigen could be from any species of virus/bactera or even human disease antigens, for example cancer antigens.

Specific projects and products

Oncolytic viruses

Main article: Oncolytic virus

The oncolytic virus Rigvir developed at the Institute of Microbiology in Latvia was registered in 2004 in Latvia (national registration).[5] This wild-type nonpathogenic enteric cytopathic human orphan type 7 (ECHO-7) virus was the first to be granted national regulatory approval[6] and since 2004 Rigvir is approved and from 2008 Rigvir is available in pharmacies of Latvia. Also in 2015 Rigvir was included into the Latvian National guidelines for treatment of skin cancer and melanoma.[7] Since 2015 Rigvir is approved in Georgia, but in 2016 it was approved in Armenia. Regarding the historical background, ECHO -7 has been studied by scientific teams in the Soviet Union (Soviet Latvia) led by Aina Muceniece with initial reports from her group in the 1960s and 1970s. The empirical roots of the soviet science and the mentioned regulatory approvals, have apparent limitations and do not appear to be supported by clinical data of the rigor that is typically warranted in the US, European Union and Japan, considered to be the most rigorous in the regulatory review of novel cancer therapeutics. However, despite these limitations on the available data, the story of Rigvir remains worth exploring with the implementation of critical reasoning, given that it is a wild-type virus, among other viruses, and hence could rapidly undergo translation if safety and efficacy can be confirmed by other investigators. For example, a potential benefit for Rigvir in comparison to T-VEC includes potential for higher specificity of cancer cells as the latter is taken up by normal cells. Again, there is currently insufficient information to compare both oncolytic viruses due to the lack of prospective and comparative trials, but the available retrospective clinical case studies demonstrate the effort being applied towards sufficient and formally acceptable scientific approval.[8] Since then Rigvir registration in Latvia has become under intense scrutiny and questioning. There are intensive local accusations of complete lack of appropriately documented efficacy, and unethical (and occasionally unlawful) practices of its sellers. However, this negative background is significantly reinforced by political and business culture distinctive for post-soviet regions, like Latvia.

In 2004, researchers from University of Texas genetically programmed a type of common cold virus Adenovirus Delta-24-RGD to attack glioblastoma multiforme. Delta-24-RGD is a replication-competent virus that is genetically engineered to induce selective cancer cell lysis. In cancer cells, Delta-24-RGD induces massive autophagy, which is required for efficient cell lysis and adenoviral spread.[9] Later other researchers[10] have tried tests on mice where 9 out of 10 mice have shown degeneration of tumours and prolonged survival. A drug grade virus was approved for clinical trials on humans in 2009.[11]

In 2006 researchers from the Hebrew University succeeded in isolating a variant of the Newcastle disease virus (NDV-HUJ), which usually affects birds, in order to specifically target cancer cells.[12] Taking together reports on NDV, there is a general indication of heterologous response of tumor and immune cells after NDV stimulation. However, it is noteworthy that the genotype of the strain applied for virotherapy seems to be, at least partially, the reason for this effect, as, for example, a genotype V NDV has shown antitumor and immunostimulatory activities.[13] The researchers tested the new virotherapy on patients with glioblastoma multiforme and achieved promising results for the first time.

Vaccinia virus, a virus credited for the eradication of smallpox, is being developed as an oncolytic virus, e.g. GL-ONC1 and JX-594.[14] Promising research results[15][16] warrant its clinical development in human patients.[17] In the conducted in vitro and mice research models, vaccinia viruses have demonstrated to induce a combined cell death of apoptosis and necrosis (especially regarding JX-594). The type of cell death is interpreted to be important for the immunogenicity and the influence on immune cells in the tumor microenvironment, promoting antitumor immune response, thus supporting the use of oncolytic vaccinia viruses for further clinical development and investigation in vivo settings for data consolidation.[18]

The experimental virotherapy that has progressed the furthest in clinical trials (as of 2013) is Talimogene laherparepvec.[19] It is based on an engineered version of herpes simplex virus which has also been engineered to express GM-CSF. This virus is being developed by Amgen who reported that a pivotal phase 3 study in melanoma had met its primary endpoint (durable response rate) with a very high degree of significance in March 2013, the first positive phase 3 study with an oncolytic virus in the western world. Talimogene laherparepvec is also the first oncolytic virus to be approved in Europe for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC, and IVM1a) with no bone, brain, lung, or other visceral disease.[20]

Viral gene therapy

ProSavin is one of a number of therapies in the Lentivector platform under development by Oxford BioMedica. It delivers to the brain the genes for three enzymes important in the production of dopamine, a deficiency of which causes Parkinson's disease.

TNFerade (a non replicating TNF gene therapy virus) failed a phase III trial for pancreatic cancer.[21]

Viral immunotherapy

Trovax is an immunotherapy that uses a pox-virus bearing the tumour antigen 5T4, to induce an immune response against a variety of cancer types. The therapy was developed by Oxford BioMedica and failed to improve overall survival in a phase 3 trial in renal cell carcinoma.[22] New phase II trials have since begun at Cardiff University (UK) with colorectal cancer and at the Velindre Cancer Centre (Cardiff, UK) with malignant pleural mesothelioma.

Protozoal virotherapy

Recent papers have proposed the use of viruses to treat infections caused by protozoa.[23][24]

History

Chester M. Southam, a researcher at Memorial Sloan Kettering Cancer Center, pioneered the study of viruses as potential agents to treat cancer.[25]

See also

References

  1. ^ Kelly, E; Russell, SJ (April 2007). "History of oncolytic viruses: genesis to genetic engineering". Molecular Therapy. 15 (4): 651–9. doi:10.1038/sj.mt.6300108. PMID 17299401.
  2. ^ Moore, AE (May 1949). "The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180". Cancer. 2 (3): 525–34. doi:10.1002/1097-0142(194905)2:3<525::AID-CNCR2820020317>3.0.CO;2-O. PMID 18131412.
  3. ^ "Clinical virotherapy: four historically significant clinical trials".
  4. ^ Huebner, RJ; Rowe, WP; Schatten, WE; Smith, RR; Thomas, LB (Nov–Dec 1956). "Studies on the use of viruses in the treatment of carcinoma of the cervix". Cancer. 9 (6): 1211–8. doi:10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7. PMID 13383455.
  5. ^ Latvian State Agency of Medicines Registry. "Medicinal product register of the Republic of Latvia". Retrieved 21 January 2015.
  6. ^ Duffy, M.R.; Fisher, K.D.; Seymour, L.W. (November 2017). "Making Oncolytic Virotherapy a Clinical Reality: The European Contribution". Human Gene Therapy. 28 (11). M.A. Liebert Country of Publication: United States NLM: 1033–1046. doi:10.1089/hum.2017.112. ISSN 1557-7422. PMID 28793793. 9008950.
  7. ^ "Cancer Virotherapy Journal". Retrieved 23 November 2015.
  8. ^ Babiker, H.M.; Riaz, I.B.; Husnain, M.; Borad, M.J. (February 2017). "Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma". Oncolytic Virotherapy. 6. Dovepress, New Zealand NLM: 11–18. doi:10.2147/OV.S100072. ISSN 2253-1572. PMID 28224120. 101629828.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  9. ^ Klein, S.R.; Piya, S.; Lu, Z.; Xia, Y.; Alonso, M.M.; White, E.J.; Wei, J.; Gomez-Manzano, C.; Jiang, H.; Fueyo, J. (January 2015). "C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy". Oncogene. 34 (41). Nature Publishing Group: 5295–5301. doi:10.1038/onc.2014.452. ISSN 0950-9232.
  10. ^ Witlox AM, Van Beusechem VW, Molenaar B, Bras H, Schaap GR, Alemany R, Curiel DT, Pinedo HM, Wuisman PI, Gerritsen WR (2004). "Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo". Clin. Cancer Res. 10 (Pt 1): 61–67. doi:10.1158/1078-0432.ccr-0609-03. PMID 14734452.
  11. ^ Clinical Trial for Delta-24-RGD for Recurrent Malignant Gliomas
  12. ^ "Viruses: The new cancer hunters". IsraCast (News article). March 1, 2006. Retrieved July 22, 2016.
  13. ^ Ortega-Rivera, O.A.; Quintanar, J.L.; Del Toro-Arreola, S.; Alpuche-Solis, Á.G.; Esparza-Araiza, M.J.; Salinas, E. (January 2018). "Antitumor and immunostimulatory activities of a genotype V recombinant attenuated veterinary Newcastle disease virus vaccine". Oncology Letters. 15 (1). Spandidos Publications, Greece NLM: 1246–1254. doi:10.3892/ol.2017.7387. ISSN 1792-1074. PMID 29399179. 101531236.
  14. ^ "Welcome to Genelux - intro". Genelux.com. Retrieved 2012-02-03.
  15. ^ Zhang, Q; Yu, YA; Wang, E; Chen, N; Danner, RL; Munson, PJ; Marincola, FM; Szalay, AA (2007). "Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus". Cancer Research. 67 (20): 10038–46. doi:10.1158/0008-5472.CAN-07-0146. PMID 17942938.
  16. ^ Kelly, KJ; Woo, Y; Brader, P; Yu, Z; Riedl, C; Lin, SF; Chen, N; Yu, YA; Rusch, VW; Szalay, Aladar A.; Fong, Yuman (2008). "Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma". Human gene therapy. 19 (8): 774–82. doi:10.1089/hum.2008.036. PMC 2940611. PMID 18754710.
  17. ^ "Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors". ClinicalTrials.gov. Retrieved 2012-02-03.
  18. ^ Heinrich, B.; Klein, J.; Delic, M.; Goepfert, K.; Engel, V.; Geberzahn, L.; Lusky, M.; Erbs, P.; Preville, X.; Moehler, M. (May 2017). "Immunogenicity of oncolytic vaccinia viruses JXGFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes". OncoTargets & Therapy. 10. Dove Press: 2389–2401. ISSN 1178-6930.
  19. ^ Study of Safety and Efficacy of OncoVEXGM-CSF With Cisplatin for Treatment of Locally Advanced Head and Neck Cancer
  20. ^ Harrington, K.J.; Michielin, O.; Malvehy, J.; Pezzani Grüter, I.; Grove, L.; Dummer, R. (August 2017). "A practical guide to the handling and administration of talimogene laherparepvec in Europe". Oncotargets And Therapy. 10. : Dove Medical Press Country of Publication: New Zealand NLM: 3867–3880. doi:10.2147/OTT.S133699. ISSN 1178-6930. PMID 28814886. 101514322.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  21. ^ "Why GenVec's TNFerade adenovector did not work in the Phase III pancreatic cancer trial?". 14 April 2010.
  22. ^ Amato, RJ; Hawkins, RE; Kaufman, HL; Thompson, JA; Tomczak, P; Szczylik, C; McDonald, M; Eastty, S; Shingler, WH; de Belin, J; Goonewardena, M; Naylor, S; Harrop, R (Nov 15, 2010). "Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study". Clinical Cancer Research. 16 (22): 5539–47. doi:10.1158/1078-0432.CCR-10-2082. PMID 20881001.
  23. ^ Keen, E. C. (2013). "Beyond phage therapy: Virotherapy of protozoal diseases". Future Microbiology. 8 (7): 821–823. doi:10.2217/FMB.13.48. PMID 23841627.
  24. ^ Hyman, P.; Atterbury, R.; Barrow, P. (2013). "Fleas and smaller fleas: Virotherapy for parasite infections". Trends in Microbiology. 21 (5): 215–220. doi:10.1016/j.tim.2013.02.006. PMID 23540830.
  25. ^ Sepkowitz, Kent (24 August 2009). "West Nile Made Its U.S. Debut in the 1950s, in a Doctor's Syringe". The New York Times. p. D5.

Further reading

  • Ring, Christopher J. A.; Blair, Edward D. (2000). Genetically engineered viruses: development and applications. Oxford: Bios. ISBN 1859961037. OCLC 45828140.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Virotherapy&oldid=836692232"